BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Total Current Liabilities
All obligations due within one year.
BioAge Labs, Inc.NASDAQ: BIOA
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 33.3% from a year ago
Total current liabilities stood at $15.83M at the end of Q1 FY2026, down 33.3% from a year earlier and down 21.4% from the prior quarter. Over 3 fiscal years it compounded at +50.9% a year.
Context
- Total current liabilities amounted to 4.0% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -33.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 20.14M USD
- Year-over-year change
- -27.5%
- 3-year CAGR
- +50.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.14M | -27.5% |
| FY2024 | 2024-12-31 | 27.78M | -52.3% |
| FY2023 | 2023-12-31 | 58.17M | +892.5% |
| FY2022 | 2022-12-31 | 5.86M | — |
Total Current Liabilities vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -33.3% is the 7th highest of 9, against a peer median of -3.9%.
- Total current liabilities amounts to 4.0% of total assets for BIOA, versus a peer median of 12.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$158.44M CAD | +67.8% | -35.0% | 14.2% | |
| Mar 2026 | CA$67.1M CAD | -39.1% | -34.4% | 11.1% | |
| Mar 2026 | $41.51M USD | +22.1% | +74.2% | 28.0% | |
| Mar 2026 | $39.78M USD | -45.6% | -8.4% | 26.6% | |
| Mar 2026 | $33.37M USD | +53.4% | +29.1% | 12.5% | |
| Mar 2026 | $28.33M USD | -5.6% | -15.4% | 7.2% | |
| Dec 2025 | $23.57M USD | — | — | 10.2% | |
| Mar 2026 | $16.19M USD | -19.2% | -2.1% | 14.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $15.83M USD | -33.3% | +50.9% | 4.0% |
| Mar 2026 | $6.9M USD | -2.1% | -11.5% | 7.0% | |
| Peer median (excluding BIOA) | — | -3.9% | -9.9% | 12.5% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.